Sign In
Buy FULC
$3.22
+0.0800 (+2.55%)
At Close: Jun 03, 2026
LOS ANGELES, CA / ACCESSWIRE / September 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Ther
Fulcrum Therapeutics (FULC) Loses -65.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Monday, 16'th Sep 2024
The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree
NEW YORK, NY / ACCESSWIRE / September 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) c
NEW YORK, NY / ACCESSWIRE / September 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company")
NEW YORK, NY / ACCESSWIRE / September 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) c
LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Ther
NEW YORK, NY / ACCESSWIRE / September 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) c
NEW YORK-, Sept. 15, 2024 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASD
NEW YORK, NY / ACCESSWIRE / September 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) c
NEW YORK, NY / ACCESSWIRE / September 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company")
Did Fulcrum Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- FULC
09:01pm, Saturday, 14'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) c
Shareholders In Fulcrum Therapeutics Inc Are Invited To Join The Schall Law Firm's Investigation Into Possible Securities Fraud
04:00pm, Saturday, 14'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Ther
LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Ther
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 13'th Sep 2024
CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives
Fulcrum Therapeutics, Inc. (FULC) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
04:30pm, Friday, 13'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) c
